<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00987974</url>
  </required_header>
  <id_info>
    <org_study_id>FMD01</org_study_id>
    <nct_id>NCT00987974</nct_id>
  </id_info>
  <brief_title>Short Term Statin Treatment and Endothelial Dysfunction Due to Ischemia and Reperfusion Injury</brief_title>
  <official_title>Short Term Statin Treatment and Endothelial Dysfunction Due to Ischemia and Reperfusion Injury</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Radboud University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Radboud University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Rationale:

      Apart from their cholesterol lowering effects, statins have cholesterol‐independent
      pleiotropic actions, such as upregulation of 5'‐ectonucleotidase and up‐regulation of
      NO‐synthase that may increase tolerance against ischemia‐reperfusion injury (IR‐injury).
      Several animal studies have shown reduction of IR‐injury as a result of statin treatment in
      both the heart and the kidney. Recently the investigators have shown, using Annexin A5
      targeting after voluntary ischemic exercise to assess IR‐injury, a protective effect of a 7
      day oral rosuvastatin treatment. A three day treatment with atorvastatin however failed to
      reduce annexin targeting.

      Assessment of the flow mediated dilation of the brachial artery as measure of endothelial
      (dys)function, is a validated model to research effects of possible protective strategies and
      perform mechanistic experiments on IR‐injury in humans in vivo.

      The investigators hypothesize that pretreatment with statins can increase endothelial
      tolerance against ischemia and reperfusion injury.

      Objective:

      To study the protective effect of pretreatment (both 3 day and 7 day) with rosuvastatin and
      atorvastatin on flow mediated dilation after 15 minutes ischemia and 15 minutes reperfusion.

      Study design: placebo‐controlled randomised double‐blind trial

      Study population: Healthy volunteers, age 18‐50

      Intervention: Treatment with either rosuvastatin 20 mg, atorvastatin 80mg or placebo during
      either 3 or 7 days

      Main study parameters: Difference in flow mediated dilation before and after 15 minutes
      ischemia.

      Nature and extent of the burden and risks associated with participation, benefit and group
      relatedness: Treatment with rosuvastatin or atorvastatin is not expected to harm the
      volunteers. Most reported side effects of rosuvastatin and atorvastatin are gastro‐intestinal
      complains and myalgia. The volunteers will not benefit directly from participating in this
      study.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">March 2010</completion_date>
  <primary_completion_date type="Actual">February 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Difference in flow mediated dilation before and after 15 minutes ischemia</measure>
    <time_frame>30 minutes</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ecto‐5'‐nucleotidase activity and lipid profile after statin therapy</measure>
    <time_frame>3-7 days</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Ischemia Reperfusion Injury</condition>
  <condition>Endothelial Dysfunction</condition>
  <arm_group>
    <arm_group_label>rosuvastatin 3days</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>8 Subjects will use rosuvastatin 20 mg/day for 3 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>atorvastatin 3 days</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>8 Subjects will use atorvastatin 80 mg/day for 3 days.pj</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo 3days</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>8 Subjects will use placebo for 3 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>rosuvastatin 7 days</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>8 Subjects will use rosuvastatin 20 mg/day for 7 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>atorvastatin 7 days</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>8 Subjects will use atorvastatin 80 mg/day for 7 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo 7 days</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>8 Subjects will use placebo for 7 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rosuvastatin</intervention_name>
    <description>rosuvastatin 20 mg/day for 3 days.</description>
    <arm_group_label>rosuvastatin 3days</arm_group_label>
    <other_name>crestor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>atorvastatin 3 days</intervention_name>
    <description>atorvastatin 80 mg/day for 3 days.</description>
    <arm_group_label>atorvastatin 3 days</arm_group_label>
    <other_name>lipitor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo for 3 days.</description>
    <arm_group_label>placebo 3days</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rosuvastatin 7 days</intervention_name>
    <description>rosuvastatin 20 mg/day for 7 days</description>
    <arm_group_label>rosuvastatin 7 days</arm_group_label>
    <other_name>crestor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>atorvastatin 7 days</intervention_name>
    <description>atorvastatin 80 mg/day for 7 days.</description>
    <arm_group_label>atorvastatin 7 days</arm_group_label>
    <other_name>lipitor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo 7 days</intervention_name>
    <description>placebo 7 days</description>
    <arm_group_label>placebo 7 days</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18‐50

          -  Written informed consent

        Exclusion Criteria:

          -  Smoking

          -  History of any cardiovascular disease

          -  Hypertension (in supine position: systole &gt;140 mmHg, diastole &gt;90 mmHg)

          -  Diabetes Mellitus (fasting glucose &gt;7.0 mmol/L or random glucose &gt;11.0 mmol/L)

          -  Hyperlipidaemia (fasting total cholesterol &gt;5.5 mmol/L or random cholesterol &gt;6.5
             mmol/L)

          -  Alanine amino transferase &gt;90 U/L

          -  Creatine kinase &gt;440 U/L

          -  Raised rhabdomyolysis risk

               -  GFR &lt;60 ml/min

               -  Overt clinical signs of hypothyroidism

               -  Myopathy in family history

               -  Alcohol abuse

          -  Concomitant chronic use of medication

          -  Participation to any drug‐investigation during the previous 60 days as checked with
             VIP check.

          -  Professional athletes
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>RUNMC</name>
      <address>
        <city>Nijmegen</city>
        <zip>6500HB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <reference>
    <citation>Meijer P, Oyen WJ, Dekker D, van den Broek PH, Wouters CW, Boerman OC, Scheffer GJ, Smits P, Rongen GA. Rosuvastatin increases extracellular adenosine formation in humans in vivo: a new perspective on cardiovascular protection. Arterioscler Thromb Vasc Biol. 2009 Jun;29(6):963-8. doi: 10.1161/ATVBAHA.108.179622. Epub 2009 Apr 9.</citation>
    <PMID>19359665</PMID>
  </reference>
  <reference>
    <citation>Kharbanda RK, Peters M, Walton B, Kattenhorn M, Mullen M, Klein N, Vallance P, Deanfield J, MacAllister R. Ischemic preconditioning prevents endothelial injury and systemic neutrophil activation during ischemia-reperfusion in humans in vivo. Circulation. 2001 Mar 27;103(12):1624-30.</citation>
    <PMID>11273988</PMID>
  </reference>
  <verification_date>April 2001</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 30, 2009</study_first_submitted>
  <study_first_submitted_qc>September 30, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 1, 2009</study_first_posted>
  <last_update_submitted>April 27, 2010</last_update_submitted>
  <last_update_submitted_qc>April 27, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 28, 2010</last_update_posted>
  <responsible_party>
    <name_title>G. Rongen</name_title>
    <organization>RUNMC</organization>
  </responsible_party>
  <keyword>ischemia reperfusion injury</keyword>
  <keyword>endothelial dysfunction</keyword>
  <keyword>statins</keyword>
  <keyword>rosuvastatin</keyword>
  <keyword>atorvastatin</keyword>
  <keyword>placebo</keyword>
  <keyword>ecto-5'-nucleotidase</keyword>
  <keyword>flow mediated dilation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Wounds and Injuries</mesh_term>
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Reperfusion Injury</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin Calcium</mesh_term>
    <mesh_term>Rosuvastatin Calcium</mesh_term>
    <mesh_term>Hydroxymethylglutaryl-CoA Reductase Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

